$327 Million is the total value of Integral Health Asset Management, LLC's 72 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SNY | New | SANOFIsponsored adr | $6,271,000 | – | 125,000 | +100.0% | 1.92% | – |
| CNC | New | CENTENE CORP DEL | $5,541,000 | – | 95,000 | +100.0% | 1.70% | – |
| EHTH | New | EHEALTH INC | $5,530,000 | – | 70,000 | +100.0% | 1.69% | – |
| NTRA | New | NATERA INC | $4,768,000 | – | 66,000 | +100.0% | 1.46% | – |
| New | CYTOKINETICS INCcall | $4,330,000 | – | 200,000 | +100.0% | 1.32% | – | |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $3,897,000 | – | 40,000 | +100.0% | 1.19% | – |
| HOLX | New | HOLOGIC INC | $3,656,000 | – | 55,000 | +100.0% | 1.12% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $3,640,000 | – | 25,000 | +100.0% | 1.11% | – |
| GH | New | GUARDANT HEALTH INC | $3,353,000 | – | 30,000 | +100.0% | 1.03% | – |
| GMED | New | GLOBUS MED INCcl a | $3,219,000 | – | 65,000 | +100.0% | 0.98% | – |
| PNTG | New | PENNANT GROUP INC | $2,892,000 | – | 75,000 | +100.0% | 0.88% | – |
| IRTC | New | IRHYTHM TECHNOLOGIES INC | $2,857,000 | – | 12,000 | +100.0% | 0.87% | – |
| BHC | New | BAUSCH HEALTH COS INC | $2,720,000 | – | 175,000 | +100.0% | 0.83% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $2,715,000 | – | 90,000 | +100.0% | 0.83% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $2,617,000 | – | 85,000 | +100.0% | 0.80% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $2,566,000 | – | 100,000 | +100.0% | 0.78% | – |
| EW | New | EDWARDS LIFESCIENCES CORP | $2,395,000 | – | 30,000 | +100.0% | 0.73% | – |
| ZLAB | New | ZAI LAB LTDadr | $2,079,000 | – | 25,000 | +100.0% | 0.64% | – |
| ACHC | New | ACADIA HEALTHCARE COMPANY IN | $2,064,000 | – | 70,000 | +100.0% | 0.63% | – |
| GKOS | New | GLAUKOS CORP | $1,981,000 | – | 40,000 | +100.0% | 0.61% | – |
| CHWY | New | CHEWY INCcl a | $1,919,000 | – | 35,000 | +100.0% | 0.59% | – |
| SWAV | New | SHOCKWAVE MED INC | $1,895,000 | – | 25,000 | +100.0% | 0.58% | – |
| DTIL | New | PRECISION BIOSCIENCES INC | $1,848,000 | – | 300,000 | +100.0% | 0.56% | – |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $1,838,000 | – | 120,000 | +100.0% | 0.56% | – |
| KURA | New | KURA ONCOLOGY INC | $1,532,000 | – | 50,000 | +100.0% | 0.47% | – |
| New | GOSSAMER BIO INCcall | $1,241,000 | – | 100,000 | +100.0% | 0.38% | – | |
| New | INOVIO PHARMACEUTICALS INCput | $1,160,000 | – | 100,000 | +100.0% | 0.36% | – | |
| GMAB | New | GENMAB A/Ssponsored ads | $1,098,000 | – | 30,000 | +100.0% | 0.34% | – |
| MCRB | New | SERES THERAPEUTICS INC | $849,000 | – | 30,000 | +100.0% | 0.26% | – |
| INSM | New | INSMED INC | $804,000 | – | 25,000 | +100.0% | 0.25% | – |
| MYOV | New | MYOVANT SCIENCES LTD | $703,000 | – | 50,000 | +100.0% | 0.22% | – |
| ALEC | New | ALECTOR INC | $316,000 | – | 30,000 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 15 | Q3 2023 | 4.7% |
| SAGE THERAPEUTICS INC | 15 | Q2 2023 | 5.0% |
| BIOMARIN PHARMACEUTICAL INC | 15 | Q2 2023 | 4.1% |
| ENVISTA HOLDINGS CORPORATION | 14 | Q3 2023 | 4.0% |
| AKERO THERAPEUTICS INC | 14 | Q3 2023 | 1.5% |
| REVVITY INC | 13 | Q3 2023 | 4.2% |
| BLUEPRINT MEDICINES CORP | 13 | Q3 2023 | 3.3% |
| PTC THERAPEUTICS INC | 13 | Q2 2023 | 1.7% |
| ELEVANCE HEALTH INC | 12 | Q3 2023 | 6.7% |
| NEVRO CORP | 12 | Q4 2022 | 4.5% |
View Integral Health Asset Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-12 |
| 13F-HR | 2022-02-02 |
View Integral Health Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.